Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 64
Summary
- Conditions
- Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 16 years and 65 years
- Gender
- Both males and females
Description
This research is being done to try to find new combinations of treatment that may be better for treating patients with this disease. It is not clear however if these treatments can offer better results than standard treatment. The study uses a "pick the winner" design to facilitate efficient screeni...
This research is being done to try to find new combinations of treatment that may be better for treating patients with this disease. It is not clear however if these treatments can offer better results than standard treatment. The study uses a "pick the winner" design to facilitate efficient screening of novel combination treatment regimens and select those meeting pre-specified criteria for testing in the phase III setting. All novel treatment options will be compared against the standard treatment for this disease: rituximab plus gemcitabine, dexemthasone, and cisplatin (R-GDP).
Tracking Information
- NCT #
- NCT02436707
- Collaborators
- Janssen, LP
- Roche Pharma AG
- Investigators
- Study Chair: Michael Crump Univ. Health Network-OCI/Princess Margaret Hospital, Toronto ON Canada Study Chair: John Kuruvilla Univ. Health Network-Princess Margaret Hospital, Toronto ON Canada
Get Well Soon